Biobehavioral Interactions between Endocannabinoid and Hypothalamicpituitary- adrenal Systems in Psychosis: A Systematic Review DOI
Marco Colizzi, Riccardo Bortoletto,

Giulia Antolini

и другие.

Current Neuropharmacology, Год журнала: 2023, Номер 22(3), С. 495 - 520

Опубликована: Авг. 3, 2023

Background: The diathesis-stress paradigm and the cannabinoid-hypothesis have been proposed as possible pathophysiological models of schizophrenia. However, they historically studied independently each other. Objective: This PRISMA 2020-compliant systematic review aimed at reappraising interplay between hypothalamic-pituitary-adrenal (HPA) axis endocannabinoid (eCB) system in psychosis- spectrum disorder risk outcome. Methods: All outcome clinical studies, concomitantly evaluating two systems psychosis-spectrum different stages illness, were gathered from electronic databases (Pubmed, Web Science, Scopus), discussed. Results: 41 eligible outputs extracted, focusing on least a biological measure (9 HPA-related studies: 4 eCB-interventional, 1 HPA-interventional, both HPA-interventional non-interventional, 3 non-interventional; 2 eCB-related non-interventional), environmental measures only (29 eCB- interventional, 28 genetic (1 study: non-interventional). Independent contributions aberrancies to physiopathology psychosis confirmed. Also, concomitant alterations systems, either genetically defined (e.g., CNR1 variation), biologically determined dysfunctional HPA or signaling), behaviorally imputed cannabis use, stress exposure, response), consistently reported psychosis. Further, complex biobehavioral perturbation was revealed not within use affecting eCB tone, exposure axis), but also across THC axis, childhood trauma signaling). Conclusion: There is need study systems’ mechanistic contribution order establish more refined relevance.

Язык: Английский

Investigating Cannabidiol’s Potential as a Supplementary Treatment for Schizophrenia: A Narrative Review DOI
Jes Sebastian Denis Völker, I. Micluția, Ramona-Cristina Vinași

и другие.

European Journal of Pharmacology, Год журнала: 2024, Номер 979, С. 176821 - 176821

Опубликована: Сен. 1, 2024

Язык: Английский

Процитировано

3
Cannabis, Endocannabinoids and Brain Development: From Embryogenesis to Adolescence DOI Creative Commons
Ricardo J. Rodrigues, Joana M. Marques, Attila Köfalvi

и другие.

Cells, Год журнала: 2024, Номер 13(22), С. 1875 - 1875

Опубликована: Ноя. 13, 2024

The endocannabinoid signalling system (ECS) plays a critical role from the very beginning of embryogenesis. Accordingly, ECS is engaged early on in nervous development, starting neurulation, supported by identification components—both receptors and enzymes controlling metabolism—at these stages. In particular, regarding brain, involved tightly regulated sequence events that comprise brain neurogenesis to neuronal migration, morphological guidance for connectivity, synaptic circuitry refinement. importance this broad across various development processes further underscored growing understanding consequences cannabis exposure at different developmental Despite considerable knowledge we have significant gaps our remain, particularly long-term impact underlying mechanisms This review provides an overview current state throughout embryogenesis adulthood, discusses exposure, especially during adolescence—a period maturation refinement coinciding with increased risk use.

Язык: Английский

Процитировано

3
Prolonged incubation with Δ9-tetrahydrocannabinol but not with cannabidiol induces synaptic alterations and mitochondrial impairment in immature and mature rat organotypic hippocampal slices DOI Open Access
Costanza Mazzantini, Lorenzo Curti, Daniele Lana

и другие.

Biomedicine & Pharmacotherapy, Год журнала: 2025, Номер 183, С. 117797 - 117797

Опубликована: Янв. 8, 2025

Язык: Английский

Процитировано

0
Effects of pharmacological inhibition of fatty acid amide hydrolase on corticosterone release: a systematic review of preclinical studies DOI Creative Commons
Christina F. Pereira, Isabelle Boileau, Stefan Kloiber

и другие.

Discover Mental Health, Год журнала: 2025, Номер 5(1)

Опубликована: Апрель 7, 2025

Язык: Английский

Процитировано

0
Cannabis Use Patterns in First Episode Psychosis and Schizophrenia: A Scoping Review and Case Series DOI
Jeff Wang Jin,

Nolan Neu,

Isaac B. Satz

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2025, Номер unknown

Опубликована: Апрель 30, 2025

Background Cannabis use is associated with psychosis development and symptom relapse in persons schizophrenia spectrum disorders (SCZ). As more U.S. states legalize cannabis products increase potency, it crucial to better understand recent patterns SCZ. Methods We conducted a scoping review of research on SCZ after January 2016 present case series six inpatients from 2023–2024. Results Scoping review: Of 672 references, nine studies (775 participants) were included; none designed characterize quantity, frequency, or type over time. measurement methodology varied widely most did not follow recommendations for measuring use. Frequency quantity at study baseline reported by these ranged widely. At least minority participants each used very frequently; 0.6±0.6 3.4±2.2 joints/day. One small detailed product among users THC (93% flower, 80% edibles, 60% concentrates) CBD (40% 20% concentrates, 13% oils). Case Series Participants (32.0±14.4 years; 83.3% diagnosed SCZ) who 2.7±2.1 days/week. All leaf (3.1±2.3 joints/day); half (all heavy users) also concentrates (33.3%) edibles (16.7%). Conclusion Only measured SCZ; methodologies varied. legalization expands potency increases, further should its consequences

Язык: Английский

Процитировано

0
Neuronal and Astrocytic Morphological Alterations Driven by Prolonged Exposure with Δ9-Tetrahydrocannabinol but Not Cannabidiol DOI Creative Commons
Elisa Landucci, Costanza Mazzantini, Daniele Lana

и другие.

Toxics, Год журнала: 2022, Номер 10(2), С. 48 - 48

Опубликована: Янв. 21, 2022

Cannabis derivatives are largely used in the general population for recreational and medical purposes, with highest prevalence among adolescents, but chronic use abuse has raised concerns. We investigated prolonged effects of Δ9-tetrahydrocannabinol (THC) cannabidiol (CBD) organotypic hippocampal slices from P7 rats cultured 2 weeks. Cell death CA1 subregion was quantified by propidium iodide (PI) fluorescence, pre-synaptic post-synaptic marker proteins were analysed Western blotting neurodegeneration astrocytic alterations NeuN GFAP immunofluorescence confocal laser microscopy. The statistical significance differences using ANOVA a post hoc Dunnett w-test (PI fluorescence intensities blots) or Newman-Keuls (immunohistochemistry data) multiple comparisons. A probability value (P) < 0.05 considered significant. Prolonged (72 h) THC CBD incubation did not induce cell caused modifications expression synaptic morphological neurons astrocytes. In particular, PSD95 reduced following 72 h increased CBD. disorganisation stratum pyramidalis (SP) complex significant number pyramidal Our results suggest that exposure different hippocampus. induced neuronal glia must draw our attention to relatively might cause, especially adolescents.

Язык: Английский

Процитировано

13
Early Blockade of CB1 Receptors Ameliorates Schizophrenia-like Alterations in the Neurodevelopmental MAM Model of Schizophrenia DOI Creative Commons
Tibor Štark, Fabio Arturo Iannotti,

Serena Di Martino

и другие.

Biomolecules, Год журнала: 2022, Номер 12(1), С. 108 - 108

Опубликована: Янв. 10, 2022

In agreement with the neurodevelopmental hypothesis of schizophrenia, prenatal exposure Sprague-Dawley rats to antimitotic agent methylazoxymethanol acetate (MAM) at gestational day 17 produces long-lasting behavioral alterations such as social withdrawal and cognitive impairment in adulthood, mimicking a schizophrenia-like phenotype. These abnormalities were preceded neonatal age both by delayed appearance reflexes, an index impaired brain maturation, higher 2-arachidonoylglycerol (2-AG) levels. Schizophrenia-like deficits reversed early treatment [from postnatal (PND) 2 PND 8] CB1 antagonist/inverse agonist AM251 (0.5 mg/kg/day). By contrast, blockade affected performance control which was paralleled enhanced 2-AG content prefrontal cortex (PFC). results suggest that MAM insult leads premorbid anomalies via altered tone endocannabinoid system, may be considered marker preceding development adulthood.

Язык: Английский

Процитировано

12
Unveiling behavioral and molecular neuroadaptations related to the antidepressant action of cannabidiol in the unpredictable chronic mild stress model DOI Creative Commons
María S. García‐Gutiérrez, Daniela Navarro,

Amaya Austrich-Olivares

и другие.

Frontiers in Pharmacology, Год журнала: 2023, Номер 14

Опубликована: Апрель 18, 2023

Introduction: This study aims to further characterize cannabidiol’s pharmacological and molecular profile as an antidepressant. Methods: Effects of cannabidiol (CBD), alone or combined with sertraline (STR), were evaluated in male CD1 mice ( n = 48) exposed unpredictable chronic mild stress (UCMS) procedure. Once the model was established (4 weeks), received CBD (20 mg·kg-1, i.p.), STR (10 p.o.) its combination for 28 days. The efficacy using light-dark box (LDB), elevated plus maze (EPM), tail suspension (TS), sucrose consumption (SC) novel object recognition (NOR) tests. Gene expression changes serotonin transporter, 5-HT1A 5-HT2A receptors, BDNF, VGlut1 PPARdelta, dorsal raphe, hippocampus (Hipp) amygdala by real-time PCR. Besides, NeuN caspase-3 immunoreactivity assessed Hipp. Results: exerted anxiolytic antidepressant-like effects at 4 7 days treatment LDB TS tests, respectively. In contrast, required 14 show efficacy. improved cognitive impairment anhedonia more significantly than STR. showed a similar effect LBD, TST EPM. However, worse outcome observed NOR SI modulates all disturbances induced UCMS, whereas could not restore 5-HT1A, BDNF PPARdelta Discussion: These results pointed out potential new antidepressant faster action efficiency Particular attention should be given current SSRI since it appears produce negative impact on treatment.

Язык: Английский

Процитировано

6
Prenatal MAM exposure raises kynurenic acid levels in the prefrontal cortex of adult rats DOI

Francesca Frescura,

Tibor Štark,

Edoardo Tiziani

и другие.

Pharmacological Reports, Год журнала: 2024, Номер 76(4), С. 887 - 894

Опубликована: Май 24, 2024

Язык: Английский

Процитировано

2
DNA methylation at cannabinoid type 1 and dopamine D2 receptor genes in saliva samples of psychotic subjects: Is there an effect of Cannabis use? DOI Creative Commons
Martina Di Bartolomeo,

Andrea Čerňanová,

Veronika Petrušová

и другие.

Pharmacological Research, Год журнала: 2024, Номер 208, С. 107343 - 107343

Опубликована: Авг. 8, 2024

Psychosis is a characterizing feature of many mental disorders that dramatically affects human thoughts and perceptions, influencing the ability to distinguish between what real not. Both genetic environmental factors, such as stressful events or drug use, play pivotal role in development symptomatology therefore changes epigenome may be relevance modeling psychotic phenotype. According well-documented dysregulation endocannabinoid dopaminergic system genes schizophrenia, we investigated DNA methylation cannabinoid type 1 receptor (CNR1) dopamine D2 (DRD2) saliva samples from subjects using pyrosequencing. The epigenetic mark was significantly higher directly correlated for both compared healthy controls. We also showed these levels were lower reporting current delta-9-tetrahydrocannabinol (THC) consumption, well-known risk factor developing psychosis throughout lifespan, resembling those controls at least DRD2 gene. Overall, our data confirm key CNR1 gene regulation suggest specific CpG sites potential biomarkers, but just not consuming THC.

Язык: Английский

Процитировано

2